References in periodicals archive ?
28 December 2011 - US generic and specialty pharmaceutical major Mylan Inc (NASDAQ:MYL) said on Tuesday its Mylan Pharmaceuticals Inc unit had obtained final US Food and Drug Administration (FDA) approval for its ANDA for Eprosartan Mesylate Tablets, 400 mg (base) and 600 mg (base), the generic version of Abbott's (NYSE:ABT) hypertension treatment Teveten Tablets.
Teveten(R) HCT is a combination of the angiotensin II receptor blocker (ARB), eprosartan mesylate, and the diuretic, hydrochlorothiazide.
Unimed currently markets Teveten(R) (eprosartan mesylate) for the treatment of hypertension, Marinol (dronabinol) as an appetite stimulant for people living with HIV disease and as an antiemetic for people with cancer, Anadrol(R)-50 (oxymetholone) for the treatment of various anemias, and Maxaquin(R) (lomefloxacin HCl), a broad-spectrum quinolone antibiotic, for both complicated and uncomplicated urinary tract infections.